alexa Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature | OMICS International
ISSN: 2329-6607
Cardiovascular Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature

Guhl EN and Jain SK*

Center for Atrial Fibrillation, Heart and Vascular Institute, University of Pittsburgh Medical Center, USA

*Corresponding Author:
Sandeep K Jain
Center for Atrial Fibrillation, Heart and Vascular Institute
University of Pittsburgh School of Medicine
200 Lothrop St. PUH B535, Pittsburgh, PA 15213, USA
Tel: 412-647-6272
Fax: 412-647-7979
E-mail: [email protected]

Received date: August 12, 2017; Accepted date: September 07, 2017; Published date: September 14, 2017

Citation: Guhl EN, Jain SK (2017) Antiarrhythmic Medications for Cardioversion and Maintenance of Sinus Rhythm in Patients with Cardiac Arrhythmias: A Review of the Literature. Cardiovasc Pharm Open Access 6:218. doi: 10.4172/2329-6607.1000218

Copyright: © 2017 Guhl EN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Cardiovascular Pharmacology: Open Access


Introduction: Cardiac arrhythmias, including supraventricular and ventricular tachycardias, portend a higher risk of morbidity and mortality. These arrhythmias also are associated with increased healthcare resource utilization, decreased quality of life, and increased activity impairment. Pharmacologic conversion is a treatment option for conversion to sinus rhythm that has the advantage of avoiding sedation from DC cardioversion.

Objective: To review the efficacy, side effects, clearance, and prescribing considerations for antiarrhythmic medications for pharmacologic cardioversion.

Methodology: We included studies evaluating the efficacy of antiarrhythmic drugs. We included prescribing indications including half-life, clearance, and side effects. We arranged the manuscript by Vaughan Williams classification.

Results: Class IA, class IC, and class III antiarrhythmic medications are effective at conversion of supraventricular arrhythmias with rates frequently greater than 50%. Amiodarone and Lidocaine may be used for conversion of ventricular tachycardias. The specific agent utilized depends upon the potential other medication interactions, clearance and toxicity.

Conclusion: Pharmacologic cardioversion provides a reasonable alternative to electrical cardioversion in many cases.


Pharmacologic cardioversion; Chemical cardioversion; Antiarrhythmic medications; Supraventricular tachycardia; Ventricular tachycardia; Atrial fibrillation


Cardiac arrhythmias including supraventricular and ventricular tachycardias account for significant morbidity and mortality in the United States and contribute to increased overall healthcare resource utilization. It is currently estimated that 5.2 million adults in the United States have atrial fibrillation with the number expected to increase to 12.1 million by the year 2030 given the aging population [1]. Other types of supraventricular tachycardia have an incidence of 35 per 100,000 persons per year [2]. Ventricular arrhythmias are seen in 15-16% of individuals with coronary artery disease, 8-9% of individuals with other cardiovascular disease and in 2-3% of individuals with no cardiac disease and carry a high morbidity and mortality, particularly from sudden cardiac death [3]. In addition to increased morbidity and mortality, all of these cardiac arrhythmias portend decreased quality of life, increased activity impairment, and increased healthcare resource utilization [4,5].

The goals of treatment differ slightly by type of arrhythmia but often involve rate control and conversion to sinus rhythm (SR) either by electrical cardioversion or with antiarrhythmic medications. For atrial fibrillation, maintenance of SR is also pursued by antiarrhythmic agents, and anticoagulants are utilized for prevention of stroke or thromboembolic events. Conversion to SR has multiple potential and theoretical benefits including alleviation of symptoms, improved hemodynamics, reduced risk of thromboembolic events, reduced morbidity and mortality, and lower healthcare resource utilization. When compared to electrical cardioversion, chemical cardioversion offers the advantage of not requiring sedation and typically medications that are successful for chemical cardioversion can be continued for maintenance of sinus rhythm.

The pathophysiology underlying cardiac arrhythmias has been studied extensively identifying many mechanisms that may serve as targets for therapy. Ion channel and transporter abnormalities lead to ectopic impulse formations making ion channels a common target for many of our current therapies [6]. Structural remodeling, particularly fibrosis, interferes with electrical activity making fibrosis formation a potential therapeutic target as well. Genome-wide association studies for atrial fibrillation have identified genetic loci that may be targets for gene therapies and personalized medicine [7]. MicroRNAs have been linked to cardiac excitability and structural remodeling [8]. Based on these mechanisms, novel therapy focusing on atrial-specific channel blockers, upstream therapy and remodeling are emerging for arrhythmias [9-11].

Due to electrophysiologic and structural remodeling that occurs with most arrhythmias, they generally become more difficult to convert with increasing duration. Thus, early conversion to SR may limit remodeling and improve efficacy of long-term treatment. In patients with hemodynamically unstable arrhythmias, electrical cardioversion is generally recommended. For this reason, many ventricular arrhythmias require electrical cardioversion given their instability though there are instances where antiarrhythmic medications can be used as an adjunct or alone if the patient is stable. In patients undergoing elective cardioversion, however, pharmacologic cardioversion may be preferred with the advantage of avoidance of potential side effects of pro-arrhythmia and sedation from DC cardioversion. However, when electing pharmacologic conversion, the side effects, clearance, and conversion efficacy of the medication used must be considered. Many of these drugs are also used for maintenance of sinus rhythm and if they fail then electrical cardioversion is generally pursued.

In the present article, we review the efficacy, side effects, clearance, and prescribing considerations of multiple antiarrhythmic medications for pharmacologic cardioversion and have organized the manuscript by Vaughan Williams classification. While Vaughan Williams classification is an imperfect classification system as most antiarrhythmic drugs have multiple modes of action, it does organize by primary mechanism and is currently the most widely accepted classification system. This review will focus on antiarrhythmic drugs for chemical cardioversion though many of the medications, particularly if successful for cardioversion, can be used for maintenance.

Class IA Antiarrhythmic Medications


Procainamide is a Vaughan Williams Class 1a antiarrhythmic agent approved for documented ventricular arrhythmias [12]. The mechanism of action involves inhibition of the rapid inward sodium current, INa. Procainamide metabolism occurs through hepatic metabolites, and elimination occurs through the renal system [13]. Procainamide has a reported reported half-life of 2.5-4.5 hours and carries a risk of hypotension, AV block, bradycardia, ventricular tachycardia, and systemic lupus erythematosus [14,15]. Nacetylprocainamide is an active metabolite of procainamide and itself has some Class III anti-arrhythmic properties [16].

Intravenous procainamide has a conversion efficacy for supraventricular tachycardias ranging from 11%-65% [14,17-20]. When divided by type of arrhythmia, the conversion rates are improved for atrial fibrillation vs. atrial flutter (42-58% vs. 14-28%). Halpern et al found that non-converters had a significantly larger left atrial size when compared to converters (4.9 cm vs. 3.0 cm) [20], while Fenster et al. found that converters had a significantly shorter mean duration of atrial fibrillation (6 vs. 79 days) [19]. Volgman et al. found a mean time to conversion of 34.4 minutes [17] and Stiell et al found a median time to conversion of 55 minutes [14].

Procainamide was found to be inferior for conversion efficacy of acute onset (<24 hours) atrial fibrillation when compared to flecainide (65% vs. 92%) [18]. The drug was also found to be inferior to ibutilide in conversion of both atrial flutter (14% vs. 76%) and atrial fibrillation (21% vs. 51%) [17]. There was no difference in conversion efficacy of atrial tachycardia for procainamide vs. amiodarone in the critically ill (71% vs. 70%) [21].

Due to side effects and concern of pro-arrhythmia in patients with significant structural heart disease, use of Class IA agents is currently limited. Rapidly conducting atrial fibrillation in the setting of Wolff- Parkinson-White Syndrome is a situation in which procainamide can be useful due to effects on the accessory pathway, atrial tissue and AV node.


Quinidine is a Vaughan Williams Class IA antiarrhythmic agent that has a mechanism of action similar to procainamide involving primarily inhibition of the rapid inward sodium current, INa but also with calcium and potassium channel blocking properties [22]. Quinidine is cleared by 60-85% by the liver, has a reported half-life of 3-19 hours and steady state plasma level achieved within 24 hours. Quinidine does carry a risk of proarrhythmia including Torsades de Pointes with a risk of 1.5% per year [23]. The most commonly reported side effects are gastrointestinal [24,25]. There is also a small but significant risk of immune-mediated drug effects including systemic lupus and vasculitis [26].

The conversion efficacy of quinidine for atrial fibrillation has been studied both alone and in conjunction with other medications. When administering quinidine alone, the conversion efficacy ranged from 40-84% [24,25,27]. Quinidine administered with digoxin had an efficacy range of 47-86% [28,29]. When administered with propranolol, Antonelli et al found the conversion efficacy rate to be 88%. (Antonelli et al., 1985) The mean time to conversion ranged from 4.0 ± 2.9 hours for quindine and digoxin to 10.8 ± 10.5 hours for quinidine alone [28,30].

When compared to propafenone in patients with persistent atrial fibrillation of <6 months, quinidine was superior in conversion to sinus rhythm (84% vs. 28%) [27]. Hohnloser et al compared quinidine to sotalol for conversion of atrial fibrillation to sinus rhythm and found quinidine to be superior to sotalol (60% vs. 20%) [24]. Borgeat et al compared quinidine to flecainide and found conversion rates of 60% vs. 67%, however, when looking at AF that has lasted longer than 10 days quinidine was superior to flecainide (40% vs. 22%) [25]. Kerin et al. compared quinidine with digoxin to amiodarone for conversion of persistent (>3 weeks) atrial fibrillation finding no significant difference between the groups (47% vs. 44%) [29].

The conversion efficacy of quinidine with digoxin has been evaluated in two studies. Halinen et al compared efficacy of sotalol to quinidine and in the quinidine group administered digoxin if the ventricular rate was >100 bpm. The quinidine group demonstrated superior efficacy to sotalol for conversion of atrial fibrillation to sinus rhythm (86% vs. 52%) [28]. Capucci et al looked at recent onset atrial fibrillation, <8 days, and found that quinidine administered with digoxin was inferior to propafenone (48% vs. 83%) [30].

Class IB Antiarrhythmic Medications


Lidocaine is a Vaughan Williams Class IB antiarrhythmic agent approved as a first line agent for ventricular tachycardia. Lidocaine is CYP3A4-mediated and cleared by the hepatic system. The drug has a reported half-life of 87-108 minutes [31]. Toxic levels of lidocaine can produce CNS side effects including parasthesia, drowsiness and seizures as well as cardiovascular effects including sinus slowing, asystole, hypotension and shock. Though the risk of side effects with lidocaine is small at about 6%, patients who are elderly, have structural heart disease or decreased hepatic clearance are more likely to experience side effects [32].

Lidocaine has not been shown to be effective in treatment of supraventricular tachycardias. Marrouche et al looked at efficacy for conversion of atrial fibrillation with high dose (1.5-2.0 mg/kg) lidocaine compared to placebo in 20 patients in a randomized doubleblind crossover study and found that none of the patients with placebo or lidocaine converted to AF [33].

While lidocaine has been the standard of care for ventricular fibrillation and ventricular tachycardia the evidence for its use is mixed with limited data from randomized trials. When lidocaine was compared to bretylium as a first line antiarrhythymic for refractory VF, lidocaine had a higher conversion rate (56% vs. 35%) but there was no significant difference in resuscitation or survival [34]. Haynes et al also looked at lidocaine in management of out of hospital VF compared to bretylium and found no significant difference in conversion to an organized rhythm (93% vs. 89%), perfusing rhythm (60% vs. 58%), or survival to hospital discharge (26% vs. 34%) [35].

In a randomized trial, ALIVE, comparing lidocaine to amiodarone as an adjunct to defibrillation in patients with out of hospital cardiac arrest, there was significantly increased surivial to hospital admission with amiodarone when compared to lidocaine (23% vs. 12%) [36], Ohshige et al. looked at use of lidocaine and epinephrine vs. epinephrine alone in patients with VF who experienced out of hospital cardiac arrest and found improved survival to discharge [37]. A similar study also found the use of lidocaine to improve chance of survival to hospitalization after out of hospital cardiac arrest with VF (38% vs. 18%), however, they did not find an improvement in survival until discharge. Both of these studies were confounded by the fact that the lidocaine had to be administered by a physician onboard EMS and in the cases without lidocaine administered there was not a physician.

A few studies question the benefit of lidocaine as treatment for cardiac arrest due to ventricular fibrillation. Weaver et al found that there was no difference in survival between patients receiving lidocaine vs. epinephrine during treatment for VF (19% vs. 20%) but survival was highest in patients who received no drug therapy (30%) possibly due to lack of delay of subsequent defibrillation shocks [38]. Herlitz et al. found in a retrospective review that treatment with lidocaine was associated with a higher rate of return of spontaneous circulation but not an increased rate of discharge from the hospital [39].

Class IC Antiarrhythmic Medications


Flecainide is a Vaughan Williams Class IC antiarrhythmic agent approved for treatment of paroxysmal supraventricular tachycardias [40]. The mechanism of action is blockade of the cardiac fast inward Na current, INa, and the rapid component of the delayed rectifier K+, IKr, current [41]. Flecainide undergoes extensive hepatic biotransformation via cytochrome P450 CYP2D6 with inactive metabolites, making up about 85%, excreted by the urine. The oral form has a bioavailability of 90-95% and the drug has a reported half life of 12-27 hours [42]. The drug has reported side effects of paresthesias, drowsiness, nausea, ventricular tachycardia, and sinus bradycardia [43]. Additionally, severe arrhythmogenic events have been shown to occur in ~9% of patients on flecainide with patients having events tending to be older and have a longer baseline QRS duration [44,45].

Muhiddin et al. suggest that flecainide may even slightly reduce cardiac output after infusion [46]. The Cardiac Arrhythmia Suppression Trial found that the rates of non-fatal ischemic events between placebo and treatment (flecainide or encainide) were the same at 21% in 1 year but the treatment group had a much greater mortality rate when compared to placebo in patients with recent MI [47-49], and therefore flecainide should be avoided in patients with structural heart disease.

Trials evaluating the conversion efficacy of flecainide have focused on patients with recent-onset (less than 1 week) supraventricular tachyarrhythmias with a reported conversion efficacy ranging from 59-95%. [18,50-54], Martinez-Marcos et al found the median time to conversion to be 25 minutes with a range of 4-660 minutes.

When Camm et al compared different supraventricular tachyarrhythmias: atrial fibrillation (90%), atrial tachycardia (100%), AV node reentry tachycardia (89%) and atrioventricular re-entrant tachycardia (80%) are generally terminated with a greater efficacy than atrial flutter (20%) [55]. Crozier et al. also noted decreased rates of conversion for atrial flutter or atrial reentrant tachycardia (42%) when compared with AF (76%) or AVRT (100%) [43].

When comparing intravenous and oral formulations, Crijns et al. found no difference in efficacy of oral vs. intravenous formulations of flecainide for acute conversion of atrial fibrillation to sinus rhythm while Alp et al did find that IV flecainide restores SR after acute AF more rapidly than oral flecainide but after 2 and 8 hours there were no significant differences [56,57].

When compared to other medications, intravenous flecainide had significantly higher conversion efficacy compared to verapamil (82% vs. 6%)[54], amiodarone (59% vs. 22%) [53], and (90% vs. 60%)[58], procainamide (95% vs. 65%) [18], and propafenone. (90% vs. 72%) [58].

A single loading dose of oral flecainide at 300mg had a superior conversion efficacy to placebo (91% vs. 48%) and amiodarone (91% vs. 37%) in 8 hours [51].


Propafenone is a Vaughan Williams Class IC antiarrhythmic agent approved for prolongation of the time to recurrence of paroxysmal atrial fibrillation/flutter and paroxysmal supraventricular tachycardia. It is a potent sodium channel blocker with weak beta-adrenergic and calcium channel blocking activity [59]. Propafenone is ~99% cleared by the hepatic system and has a reported half-life of 2-12 hours [59-61]. The drug is contraindicated in patients with hepatic dysfunction, brochospastic disorder [62], heart failure [63,64], or bradycardia and is therefore rarely utilized in patients with significant structural heart disease. Reported side effects include hypersensitivity reactions, lupus-like syndrome, agranulocytosis, CNS disturbances, lightheadedness, a metallic taste and bronchospasm [59,65,66].

Approximately 7-10% of Caucasians, 2-7% of African Americans, and 1% of Asians lack the capacity to metabolized CYP2D6 substrates and are classified as poor metabolizers. Increased exposure may lead to cardiac arrhythmias and exaggerated beta-adrenergic blocking activity and thus because of propafenone’s metabolism by CYP2D6, the deficiency of this isoenzyme is potentially hazardous [67,68].

When studying conversion after a single loading oral dose of propafenone, the conversion rate ranged from 57% to 86% depending on the follow-up after administration of propafenone [30,69-74]. Most studies have utilized a single oral dose of 600mg [30,71,73,74], however Azpitarte used a dose of 450, 600 or 750 mg based on weight and Botto et al used either 450 or 600mg. When comparing the 450 and 600 mg doses, Botto et al found that the conversion rate for the 600mg dose was superior at 2 hr (43% vs. 8%) but not at 8 hr (57% vs. 46%) [70]. Boriani et al found the conversion rate of oral propafenone was 55% compared to IV propafenone at 41% though this was not statistically significant [73]. Later, Botto et al did find that while IV propafenone was more effective than oral at 1 hour (48% vs. 15%), there was a significantly higher conversion rate for oral vs. IV propafenone at 8 hours. (78% vs. 48% at 8 hours, p<0.01) [75].

Multiple studies found propafenone to be superior to placebo for CCV at all-time points studied [30], however two studies found that propafenone was superior to placebo in the short-term but not the long-term [70]. Azipitarte et al. found propafenone to be superior at 1 and 6 hours but not 12 or 24 hours. Botto et al. found propafenone was superior at 2 hours, 4 hours, and 8 hours but not at 24 hours. The drug was also found to be superior to digoxin plus quinidine at 12 hours (83% vs. 48%, p<0.05) [30] and to digoxin alone [72]. The mean time to conversion for propafenone ranged from 110 ± 59 min [70] to 267 ± 238 min [30,70,71,73,74].

Class III Antiarrhythmic Medications


Amiodarone is an antiarrhythmic agent approved for life threatening ventricular tachyarrhythmia and atrial arrhythmias. Although specified as a class III Vaughan Williams antiarrhythmic with inhibition of outward potassium channels, it also has significant class I and class II activity. Amiodarone is tacked up quickly and extensively by the extravascular tissues giving the intravenous form a short half life but a long elimination period [76]. However, after long term oral therapy, it has a half life of up to 60 days [77]. The drug has demonstrated safety in patients with structural heart disease and severe left ventricular hypertrophy but it does carry a risk of hypotension (11.1%)[78], phlebitis at the infusion site with the IV form (15.7%) [78], abnormalities in thyroid function (1.2%) elevated hepatic enzyme levels (1.2%), and severe pulmonary fibrosis (1.2%) [79]. Singh et al. found that there was no significant difference in overall mortality for amiodarone vs. placebo in patients with congestive heart failure and asymptomatic ventricular arrhythmia [80].

The conversion for SVT with amiodarone has been reported to range from 47%-80% [52,78,80,81], with a median time to conversion of 5.5-8.7 hours [52,80,81].

Amiodarone has been shown to be superior to placebo in conversion of atrial fibrillation in multiple randomized clinical trials. Vardas et al. found amiodarone superior to placebo in conversion of AF (80% vs. 40%) with patients who successfully converted having a short median AF duration (14 hours vs. 1440 hours) [78].

Similarly, Peuhkurinen et al. found amiodarone to be superior to placebo (50% vs. 20%) in patients with recent-onset (<48 hours) AF [81]. Amiodarone has been reported to have lower conversion rates compared to flecainide and propafenone (64% vs. 90% vs. 72%)[52], in patients with recent onset AF but it does carry the advantage of being first-line therapy approved for special patient populations including those with heart failure or severe left ventricular hypertrophy [82].

Amiodarone is widely used and effective for ventricular arrhythmias. As discussed previously, amiodarone was compared to lidocaine in the treatment of out-of-hospital ventricular fibrillation in the ALIVE trial and found to lead to substantially higher rates of survival to hospital admission [36].


Dofetilide is a Vaughan Williams Class III antiarrhythmic agent approved for maintenance of sinus rhythm in patients with atrial fibrillation (AF) or atrial flutter (AFL) and for chemical cardioversion to sinus rhythm. The mechanism of action is blockade of the delayed rectifier potassium current, IKr. Dofetilide is ~80% cleared by the renal system, has a reported half-life of ~10 hours and steady state plasma level achieved in 2-3 days [83].

The drug has demonstrated both safety and efficacy in patients with coronary artery disease [84], and left ventricular dysfunction [85-87], but it does carry a risk of QT prolongation and Torsades de Pointes (TdP) and thus requires in-hospital initiation for 6 doses on continuous telemetry with QT monitoring on 12-lead ECGs after each dose. Initial dosing should be based on CrCl and adjusted with changing renal function or QTc prolongation. In the landmark SAFIRE-D trial, dose adjustments were required in 33% of patients due to change in CrCl or prolonged QTc [88].

The incidence of TdP in patients on dofetilide ranges from 0.9%-3.3% [85,87,88]. The DIAMOND trials were a set of randomized, intention-to-treat, double-blind, placebo-controlled trials that evaluated the efficacy of dofetilide in high risk patients with either heart failure (DIAMOND-CHF) [85], or recent MI (DIAMOND-MI) [87]. Dofetilide was found to have a neutral all-cause morality risk of 41% vs. 42% reported in DIAMOND-CHF[85] and 31% vs. 32% reported in DIAMOND-MI [87], compared to placebo. Abraham et al noted risk factors, however, for an increase in one-year mortality including patients with TdP during loading compared to those without (17.6% vs. 3% at 1 year) [89]. Bendorp et al. found that baseline QTc <420 ms was associated with a marked reduction in mortality in patients with LV systolic dysfunction (RR 0.4, 95% CI 0.3-0.8) and that there was an increased risk of mortality with a baseline QTc >479 ms (RR 1.3, 95% CI 0.8 to 1.9) [90]. Pedersen et al. further expanded on the risk factors for TdP in patients on dofetilide with another DIAMOND-HF substudy. They found in addition to baseline QTc (OR 1.14, 95% CI 1.00-1.30 per 10 ms), that female gender (OR 2.2, CI 1.0-5.0) and NYHA Class III or IV HF (OR 3.2, CI 1.2-8.6) were risk factors for TdP [91].

Rates of successful CCV with dofetilide have been reported to range from 29%-77% [88,92-95], and typically takes ~2 ± 1 doses for conversion [92,93,95], with 21% of patients converting after the first dose of the drug [92]. Multiple studies have noted the rate of chemical cardioversion (CCV) to increase in a dose-dependent manner, the SAFIRE-D trial noted rates of 29.9% for 500 mcg BID, 9.8% for 250 mcg BID and 6.1% for 125 mcg BID [88,93]. Dofetilide has been noted to be more effective for CCV in AFL than AF with reported comparisons of 65% vs. 25% [95], and 75% vs. 22% [96].

Malhotra et al. studied CCV during loading vs. DC cardioversion (DCCV) for durability of maintaining sinus rhythm and found that CCV was an important predictor of durable response when compared to DCCV [97]. After CCV to SR with dofetilide, reports of the rate of maintenance of sinus rhythm at one year range from ~1/3 of patients to 58% [88,94]. Our group found that patients who converted to sinus rhythm (SR) after a single dose had a higher risk of toxicity vs. those who converted at subsequent doses with 71% of those who converted after 1st dose developing significant QT prolongation requiring dose adjustment [92].


Ibutilide is a Vaughan Williams Class III antiarrhythmic agent approved for the treatment of atrial fibrillation and atrial flutter [98]. The mechanism of action is increase in action potential duration by blocking the rapid component of the cardiac delayed rectifier current, IKr [98,99]. Ibutilide is intravenously delivered given its high first pass metabolism resulting in poor bioavailability of the oral form. Ibutilide has a high systemic plasma clearance that approximates liver blood flow[100], is excreted by the renal system and has a reported half-life of 2-12 hours [98].

The drug has demonstrated both safety and efficacy in patients heart failure [100], however, given that ibutilide causes a dose- and concentration related increase in QT interval, it does carry a risk of TdP in ~4-8.3% of patients [100,101], and extrasystole in 4.8-9% of patients [17,98,102].

The conversion rate for ibutilide for SVT has been reported to be from 31%-58% [100-103] with improved conversion of atrial flutter over atrial fibrillation (61-76% vs. 31-51%) [101]. Patsillinakos et al looked at the concomitant administration of magnesium with ibutilide and found that the addition of magnesium lead to a 13.7% improvement in the success rate of conversion with ibutilide [104]. The mean conversion time to SR after ibutilide administration ranges from 13-25 minutes [17,102].

Multiple studies have found ibutilide to be superior to placebo for conversion of AF and AFL [100,101]. When compared to procainamide, Volgman et al. found that ibutilide was more effective for the conversion of AF and AFL to SR (58.3% vs. 18.3%, p<0.0001) [17]. Vos et al. compared ibutilide efficacy to sotalol finding ibutilide superior for both AFL (70% vs. 19%) and AF (44% vs. 11%, p<0.01) [102]. Standard administration of ibutilide requires close monitoring for 4-6 hours in a unit with continuous telemetry able to provide rapid external defibrillation due to the risk of tdP.


Sotalol is a non-selective is a nonselective β-Blocker with Vaughan Williams Class III activity antiarrhythmic agent approved for maintenance of sinus rhythm in patients with symptomatic atrial fibrillation or flutter and treatment of documented life-threatedning ventricular arrhythmias [105,106]. The oral form is almost 100% bioavailable with 0% binding to plasma proteins and the half-life is 10-20 hours. Sotalol and is renally excreted and thus the daily dose must be reduced in renal failure [107].

The major risk is of torsades de pointes due to QT prolongation with studies showing a dose dependent increase in QT and QTc [105,108]. It also is associated with fatigue, lightheadedness, headache, weakness, nausea, shortness of breath and bradycardia. The drug should be avoided or used with caution in conjunction with other QT prolonging agents. Sotalol is often initiated as an inpatient to allow monitoring for pro-arrhythmia and QT prolongation but has been shown to be feasible as an outpatient with transtelephonic monitoring [108,109].

The conversion efficacy for sotalol varies dependent on arrhythmia with efficacy rates reported for SVT of 67-86% [110,111], atrial fibrillation conversion rates of 11-52%, and an atrial flutter conversion rate of 24%Mean time to conversion with sotalol is 10.2 ± 7.6 hours [28,102,111,112].

When compared to placebo, sotalol has an increase conversion efficacy rate for SVT (67% vs. 14%) [110], but not AF (11% vs. 14%) [111]. Additionally sotatol demonstrated decreased efficacy for conversion of AF when compared to quinidine (52% vs. 86%) [28], and ibutilide (11% vs. 44%) [102]. In the SAFE-T trial atrial fibrillation conversion and maintenance efficacy of amiodarone vs. sotalol was studied in a double blind placebo-controlled trial. Sotalol and amiodarone were similar in conversion efficacy (24.2% vs. 27.1%) and superior to placebo (0.8%), however, amiodarone was superior to sotalol for long-term maintenance of sinus rhythm [112].


Vernakalant, a novel antiarrhythmic, is an atrial-selective and mixed dose-, rate- and voltage-dependent Na+ and K+ channel blocker [113]. Due to its high affinity to ion channels in atrial over ventricular tissue, it is thus thought to have a lower proarrhythmic potential than other antiarrhythmic medcations. Vernakalant has been approved for pharmacologic cardioversion of recent-onset AF (≤ 7day) and postoperative AF (≤ 3 days) in the European Union but is not yet approved in the US. The drug is contraindicated in patients with hypotension (SBP<100), severe aortic stenosis, NYHA III and IV heart failure, QT prolongation, or acute coronary syndrome in the past 30 days. Vernakalant is associated with dysgeusia (7-19%), sneezing (3-16%), cough (3-6%) hypotension (1-20%), QT prolongation, and bradycardia (2-14%) [114-117].

A series of double-blind, placebo-controlled phase III trials were performed randomized to vernakalant vs. placebo (ACT I-III) [114,116,117] with 336, 160 and 262 patients, respectively. The ACT I and III studies evaluated patients with recent-onset AF while ACT II focused the conversion efficacy in post-operative patients (1-7 days) for CABG or valvular surgery. All three studies found vernakalant to be superior to placebo; ACT I (52% vs 4%), ACT II (47% vs. 14%) and ACT III (51% vs 3.6%,) when considering patients converted from AF to SR within 90 minutes. The median time to conversion ranged from 8-12 minutes and 75%-82% of those who converted did so after the first dose [116,117].

ACT IV was an open-label phase IV trial looking at 167 patients with a conversion efficacy of 51% and a median time to conversion of 14 minutes [115]. There was an improvement in conversion rates for patients with AF ≤ 48 hrs vs. > 7 days (57.9% vs 11.6%). In the ARVO trial, a Phase III trial comparing efficacy of vernakalant to amiodarone, vernakalant was found to be superior for rapid conversion of AF to SR (51.7% vs. 5.2% conversion in first 90 min) with a median conversion time of 11 minutes [114]. The patients in the ARVO trial also reported improvement in reduction of symptoms at 2 hours with vernakalant (53.4% vs. 32.8%).

Class V Antiarrhythmic Medications


Adenosine is an antiarrhythmic agent approved for diagnosis and treatment of supraventricular tachycardia. Adenosine is an endogenously occurring nucleoside whose antiarrhythmic action is mediated at the cellular level through potassium channels leading to hyperpolarization of the membrane potential in atrial myocytes [118]. In addition to coronary vasodilation, adenosine also depresses SA and AV node activity, atrial contractility, and ventricular automaticity [119]. The drug is administered intravenously and has an extremely short half-life of 0.6-1.5 seconds making most adverse reactions clinically insignificant. [119,120].

The drug is most commonly associated with dose-dependent symptoms of dyspnea, flushing and chest discomfort but symptoms typically last less than 60 seconds [119-121]. Rare side effects include bronchospasm, atrial fibrillation, and NSVT. In addition to treatment of paroxysmal supraventricular tachycardias, adenosine plays a role in diagnosis. The drug terminates the vast majority of AV node dependent tachycardias producing AV block that will reveal intratrial arrhythmias. DiMarco et al demonstrated high specificity and sensitivity as well as safety of adenosine in the diagnosis of patients presenting with narrow-complex tachycardia by distinguishing between atrial tachycardias and those that require the AV node [122,123].

The conversion efficacy at doses of 3, 6, 9, and 12 mg cumulative adenosine respectively is 35.2%, 62.3%, 80.2%, and 91.4% [124]. Other studies found similar results with the cumulative efficacy ranging from 94-100% [125,126]. When compared to verapamil for the conversion of paroxysmal SVT to SR, DiMarco et al found that adenosine was similar in efficacy but more rapid in onset of action. Two additional retrospective studies also looked at termination of paroxysmal SVT with adenosine vs. verapamil and found that adenosine had a slightly higher success rate in conversion efficacy (94% vs. 81%) [126], and (100% vs. 91%) [125]. Adenosine offers some potential advantages to verapamil including faster onset of action, short half-life resulting intransient duration of side effects, and relative absence of adverse hemodynamic effects.


Pharmacologic cardioversion provides a reasonable alternative to electrical cardioversion in many cases. As outlined, the specific agent utilized often depends upon the potential other medication interactions, clearance and potential toxicity.

The results of our review show that class IA, class IC, and class III antiarrhythmics are effective at conversion of supraventricular arrhythmias with rates frequently greater than 50%. (Table 1) Randomized controlled trials for ventricular arrhythmias are more difficult to perform given the ethics of deviating from the current standards due to the life-threatening nature of these arrhythmias.

  Half Life Clearance Conversion Rate Side Effects
Class IA
Procainamide 2.5-4.5 hours renal
AF: 42-58% AFL: 14-28%
hypotension, AV block, bradycardia, ventricular tachycardia, systemic lupus erythematous
nQuinidine 3-19 hours hepatic, renal AF: 40-84% proarrhythmia including TdP, gastrointestinal side effects, systemic lupus erythematous, vasculitis
Class IB
Lidocaine 87-108 minutes hepatic VT/VF: 56-93% sinus slowing, asystole, hypotension, shock
Class IC
Flecainide 12-27 hours hepatic, renal SVT: 59-95% paresthesias, drowsiness, nausea, ventricular tachycardia, sinus bradycardia
Propafenone 2-12 hours hepatic SVT: 57-86% hypersensitivity reactions, lupus-like syndrome, agranulocytosis, CNS disturbances, lightheadedness, metallic taste
Class III
Amiodarone IV: 3- 80 hours Oral 60 days hepatic SVT: 47%-80%
hypotension, phlebitis at injection site, thyroid abnormalities, pulmonary toxicity, elevated hepatic enzyme levels
Dofetilide 10 hours renal, hepatic SVT: 29-77% proarrhythmia including TdP
Ibutilide 2-12 hours
SVT: 31-58% proarrhythmia including TdP
Sotalol 10-20 hours renal SVT: 67-86% AF: 11-52% AFL: 24% fatigue, lightheadedness, weakness, nausea, bradycardia, dyspnea, headache
Vernakalant 3-4 hours renal, hepatic AF: 47-52% dysgeusia, sneezing, cough, hypotension, QT prolongation, bradycardia
Class V
0.6-1.5 seconds
converted to inosine and AMP SVT: 91-100% dyspnea, flushing, chest discomfort, bronchospasm, AF, NSVT

Table 1: Summary of Antiarrhythmic Medications.

Novel therapies targeting fibrosis formation, upstream therapies, gene therapy and personalized medicine are emerging as potential treatments for arrhythmias. Continued drug development will be important to enhance efficacy of conversion in addition to minimizing toxicity, as there still exist significant unmet needs in this field.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 3rd World Heart Congress
    April 19-20, 2018 Amsterdam, Netherlands
  • 2nd World Heart Congress
    May 14-16, 2018 Tokyo, Japan
  • 24th Annual Cardiologists Conference
    June 11-13, 2018 Barcelona, Spain
  • 3rd International Conference on Cardiovascular Medicine and Cardiac Surgery
    July 05-06, 2018 Berlin, Germany
  • 25th Annual Congress on Cardiology and Medical Interventions
    July 16-17, 2018 Atlanta, USA
  • 6th Global Experts Meeting on Cardiology and Cardiovascular Pharmacology
    September 24-25, 2018 Tokyo, Japan
  • Current and Future trends in Cardio Vascular Diseases: Research and Outcomes
    October 05-06, 2018 Los Angeles, USA

Article Usage

  • Total views: 458
  • [From(publication date):
    October-2017 - Feb 23, 2018]
  • Breakdown by view type
  • HTML page views : 420
  • PDF downloads : 38

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version